Evoke Wealth’s Cytokinetics CYTK Stock Holding History

Evoke Wealth’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-505	Closed	-$24K	–	548
2022 Q3	$24K	Hold	505	–	–	﹤0.01%	615
2022 Q2	$20K	Hold	505	–	–	﹤0.01%	646
2022 Q1	$19K	Hold	505	–	–	﹤0.01%	660
2021 Q4	$23K	Hold	505	–	–	﹤0.01%	660
2021 Q3	$18K	Buy	+505	New	+$14.9K	﹤0.01%	653

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Evoke Wealth's CYTK Position: Q4 2022 in Review

Evoke Wealth sold out of Cytokinetics (CYTK) in Q4 2022, closing a stake of 505 shares — an estimated $24K sold.

Evoke Wealth first reported a position in CYTK in Q3 2021 and held it in 5 quarters. The position peaked at $24K in Q3 2022. 277 funds tracked by Wall St. Rank hold CYTK as of Q4 2022.

Evoke Wealth reported no remaining Cytokinetics position as of Q4 2022 after selling out during the quarter.
Evoke Wealth sold 505 Cytokinetics shares in Q4 2022, an estimated $24K.
Evoke Wealth first reported a position in Cytokinetics in Q3 2021 and held it in 5 quarters.
Evoke Wealth's Cytokinetics position peaked at $24K in Q3 2022.
277 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2022.

Based on Evoke Wealth's 13F filing for Q4 2022, filed 10 Feb 2023.